Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
HOME > COMMENTARY
COMMENTARY
- Cell Therapy Makers Working to Stand Out from Rivals by Reducing Burdens on Hospitals
April 16, 2019
- Building Credible, Convincing System Holds Key for Japan’s Cost-Effectiveness Assessment
April 2, 2019
- Generic Makers Shifting to Focus on “Specialty Area” Faced with Tougher Business Environment
March 4, 2019
- Restructuring, Divestment Progress in Wake of Drug Pricing Overhaul
February 20, 2019
- 2019 Likely to Herald Burst of “Regenerative Medicine” Approvals
January 11, 2019
- LDP Draws Up Tax Reform Outline, Revamps Credits for R&D Expenses
December 17, 2018
- After Thumbs-Up Given to Shire Buy, Weber’s Leadership Will Now Be Put to Test
December 12, 2018
- Does Dissolution of Japan Vaccine Signal Demise of Model in Vaccine Industry Vision, or Will a Second Round of JV Take Place?
November 27, 2018
- There’s Room for Growth in Biosimilar Space, but Who Will Grab It?
August 3, 2018
- Astellas/Daiichi Sankyo Showdown Looms as Their FLT3 Inhibitors Near Approval
July 12, 2018
- LDP Heavyweights on Guard for Push to Scrap Coverage for Patch Medications
July 5, 2018
- Kudos to MHLW for Creating New Confab, but 1st Meeting Stirs Industry Frustration
May 30, 2018
- Japan Trains Sight on CEA as Centerpiece of This Year’s Cost Containment Efforts
April 23, 2018
- With Drug Price Cuts Done, MHLW Now Running Ministry-Wide Initiative to Shave Prescriptions
April 4, 2018
- Will Drug Makers Move to Pull Plug on Off-Patent Brands under “G1” Scheme?
March 12, 2018
- With CiCLE Program Entering 2nd Year, AMED Should Release More Information on Grant Program
February 28, 2018
- Chuikyo Moving toward Conclusion on Issue of Insurance Coverage for Heparinoid Drugs
January 15, 2018
- Pricing Reform Could Goad Drug Makers to Focus Resources on PMP Hopefuls
December 28, 2017
- Unraveling MHLW/MOF Tug-of-War on Drug Pricing Reform
November 8, 2017
- With Study Group on Counterfeit Drugs to Resume Discussions this Fall, Full-Scale Discussions on Introduction of PIC/S GDP Guidelines Looming
October 10, 2017
ページ
The female manager ratio at foreign drug makers in Japan has been on the steady rise since the enforcement in April 2016 of the Act on Promotion of Women’s Participation and Career Advancement in the Workplace. Women now account for…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Earlier this year, I attended a conference discussing the trends of Japan’s pharmaceutical industry. The objective of the conference was to determine what Japanese pharmaceutical companies were doing, and what they could be doing, to make themselves more competitive on…